Xenon pauses phase 3 depression trials after psychosis events
📍 Where it landed
{ "epilogue": "Following the trial setback and pause in depression drug studies due to side-effect concerns, Xenon shares fell sharply. Alongside this update on its psychiatry clinical program, the company also announced an NDA submission to the FDA for azetukalner for focal seizures." }
Epilogue added 26d ago, after coverage quieted.
The reporting (7)
-
-
-
-
-
-
-
Xenon pauses phase 3 depression trials after psychosis events fiercebiotech.com · 49d ago broke it first
Where it stands
- Velocity & Diffusion: Coverage escalated across 6 distinct news outlets with 7 published articles, achieving a live velocity of 4.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Xenon pauses phase 3 depression trials after psychosis events" developed substantial multi-source reporting across the Business sector, tracked across 6 distinct newsrooms by Newsylist.
Key reporting was led by BioPharma Dive, Yahoo Finance, Investor's Business Daily and Barron's. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.
Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 26d ago.
Answered
What drove coverage for Xenon pauses phase 3 depression trials after psychosis events?
Coverage spiked when 6 independent newsrooms published 7 verified reports during this coverage cycle.
How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.